Literature DB >> 7334372

The action of adenosine analogs on PC12 cells.

G Guroff, G Dickens, D End, C Londos.   

Abstract

PC12 cells, a nerve growth factor-responsive clone of rat pheochromocytoma, contain a membrane-bound adenylate cyclase, which can be activated by adenosine analogs. The characteristics of the cyclase response indicate the presence of stimulatory adenosine receptors. Adenosine analogs also produce a marked increase in the ornithine decarboxylase levels of the cells, and the characteristics of this response suggest that it is linked to the adenylate cyclase-stimulatory adenosine receptors. The ornithine decarboxylase response elicited by 5'-N-ethylcarboxamideadenosine (NECA), a potent stimulatory adenosine analog, is synergistic with that produced by nerve growth factor. Differentiation of the cells with nerve growth factor, however, does not substantially alter either the response of cyclase to the adenosine analog or the magnitude of the adenosine-evoked ornithine decarboxylase response. Treatment of the cells with NECA produces an increase in the phosphorylation of a specific non-histone nuclear protein. While causing little or no morphological alteration by itself, NECA is synergistic with nerve growth factor in producing neurite outgrowth in PC12 cells. NECA does not cause an induction of acetylcholinesterase in the cells. NECA does not cause an induction of acetylcholinesterase in the cells, nor does it appear to affect the induction of this enzyme by nerve growth factor.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7334372     DOI: 10.1111/j.1471-4159.1981.tb06312.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  20 in total

1.  Activation of Trk neurotrophin receptors in the absence of neurotrophins.

Authors:  F S Lee; M V Chao
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

2.  Functional characterization of adenosine A2 receptors in Jurkat cells and PC12 cells using adenosine receptor agonists.

Authors:  I van der Ploeg; S Ahlberg; F E Parkinson; R A Olsson; B B Fredholm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-02       Impact factor: 3.000

Review 3.  The mode of action of nerve growth factor in PC12 cells.

Authors:  A Levi; S Biocca; A Cattaneo; P Calissano
Journal:  Mol Neurobiol       Date:  1988       Impact factor: 5.590

4.  A new site and mechanism of action for the widely used adenylate cyclase inhibitor SQ22,536.

Authors:  Andrew C Emery; Maribeth V Eiden; Lee E Eiden
Journal:  Mol Pharmacol       Date:  2012-10-10       Impact factor: 4.436

5.  Neurosecretory habituation in PC12 cells: modulation during parallel habituation.

Authors:  P T Martin; D E Koshland
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

6.  Mutants of PC12 cells with altered cyclic AMP responses.

Authors:  T Block; C Kon; B M Breckenridge
Journal:  Mol Cell Biol       Date:  1984-10       Impact factor: 4.272

7.  Functionalized congeners of 1,3-dipropyl-8-phenylxanthine: potent antagonists for adenosine receptors that modulate membrane adenylate cyclase in pheochromocytoma cells, platelets and fat cells.

Authors:  D Ukena; J W Daly; K L Kirk; K A Jacobson
Journal:  Life Sci       Date:  1986-03-03       Impact factor: 5.037

8.  Clonal variants of PC12 pheochromocytoma cells with defects in cAMP-dependent protein kinases induce ornithine decarboxylase in response to nerve growth factor but not to adenosine agonists.

Authors:  R Van Buskirk; T Corcoran; J A Wagner
Journal:  Mol Cell Biol       Date:  1985-08       Impact factor: 4.272

9.  Regulation of neurosecretory habituation in PC12 cells: parallel pathways used by cAMP and calcium.

Authors:  P T Martin; D E Koshland
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

10.  Adenosine-dependent activation of tyrosine hydroxylase is defective in adenosine kinase-deficient PC12 cells.

Authors:  R Erny; J A Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.